Stock Market Today: Dow Losses Mount As Nasdaq Gives Up Gains; This Gold Stock Breaks Out (Live Coverage)

U.S. major indexes, including the Dow Jones Industrial Average which fell 0.7%, weakened on Thursday as investors reacted to President Trump's proposed chip tariffs. Despite the broader market pressure, individual stocks saw significant volatility; Eli Lilly plunged 14% on an obesity drug setback, while Fortinet gained after reporting Q2 earnings, revenue, and billings that exceeded estimates.

Analysis

U.S. major indexes, including the Dow Jones Industrial Average which declined 0.7%, weakened under pressure from President Trump's proposed chip tariffs, creating significant cross-currents in the market. While the tariff news negatively impacted chip stocks like Intel, the sector exhibited notable divergence, with Taiwan Semiconductor and Apple both rising, the latter also buoyed by a new U.S. investment commitment. The market was further characterized by powerful, company-specific catalysts that overshadowed broader trends. In the healthcare sector, Eli Lilly shares plunged 14% on a major setback for its obesity drug, while LifeMD plummeted 40%, highlighting extreme volatility and binary risk in the weight-loss treatment space. Conversely, the cybersecurity sector saw mixed signals; Fortinet's Q2 earnings, revenue, and billings surpassed estimates, but reports of investor confusion over its firewall refresh cycle contributed to a broader sell-off among its peers, indicating that even positive results are being met with deep scrutiny.

Key Decisions for Investors

• Investors should exercise caution as geopolitical tariff announcements are demonstrably driving broad market weakness and creating specific headwinds for the domestic semiconductor industry.
• The sharp, disparate stock reactions within the chip sector suggest a need to analyze individual company exposure to trade policy rather than trading the sector as a monolith.
• The severe declines in Eli Lilly (-14%) and LifeMD (-40%) underscore the high binary risk in the pharmaceutical sector, particularly for companies with significant value tied to specific drug pipelines like obesity treatments.
• Fortinet's complex reception, despite beating estimates, indicates investors must look beyond headline earnings and scrutinize forward-looking guidance and product cycle health for technology companies.